Our services

Mounjaro in the UAE: What It Is, How Tirzepatide Works and Who It May Suit

Picture of Dr. Hecham Harb

Dr. Hecham Harb

Consultant Endocrinologist & Medical Director

Mounjaro Injection in UAE - Price, Benefits, Where to Buy & More

Select your location

Book Your Consultation

Quick answer

Mounjaro is a once-weekly injection of tirzepatide, available in the UAE on prescription at every strength from 2.5 mg to 15 mg. Tirzepatide acts on two hormone receptors, GIP and GLP-1, which can reduce appetite and food intake. In SURMOUNT-1, a 72-week clinical trial in adults with obesity or overweight, patients on the highest dose lost around 20% of their body weight on average. Your endocrinologist will assess whether Mounjaro is suitable for you.

Key takeaways
  • Mounjaro is the brand name of tirzepatide, a once-weekly injection available in the UAE on prescription at every strength from 2.5 mg to 15 mg.
  • The European Medicines Agency (EMA) authorises Mounjaro for weight management in adults with a body mass index (BMI) of 30 or above, or 27 or above with a weight-related condition.
  • Treatment starts at 2.5 mg, and the maintenance doses approved by the US Food and Drug Administration (FDA) are 5 mg, 10 mg and 15 mg once weekly.
  • Digestive side effects such as nausea and diarrhoea are reported more often than others and can be particularly pronounced in the first few days at a new dose.
  • The NHS advises stopping tirzepatide at least four weeks before you start trying to become pregnant.
  • The UAE pharmacy price of Mounjaro is AED 1,734 per month, the same at every dose from 2.5 mg to 15 mg.
In one line: Mounjaro is the only weight loss medication available in the UAE that acts on both the GIP and GLP-1 receptors.

01  Introduction

Our endocrinologists prescribe Mounjaro for weight management alongside a reduced-calorie diet and increased physical activity.

Mounjaro is the brand name of tirzepatide, a medication made by Eli Lilly. In the UAE, Mounjaro is available on prescription at every strength from 2.5 mg to 15 mg.

The European Medicines Agency information on Mounjaro sets out two approved uses. Mounjaro is authorised for weight management in adults with a BMI of 30 or above, or a BMI of 27 to under 30 with at least one weight-related condition. It is also authorised for type 2 diabetes in adults, adolescents and children aged 10 and older.

In the United States, the FDA has approved Mounjaro for type 2 diabetes in adults and in children aged 10 and older. For weight management, the same medication is approved there under a second brand name, Zepbound.

Tirzepatide acts on two hormone receptors in the body: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. The Mounjaro prescribing information describes tirzepatide as binding to and activating both receptors.

GIP and GLP-1 are hormones that the gut releases after eating. Both help regulate the release of insulin, and GLP-1 also acts on appetite and on how quickly the stomach empties. The prescribing information reports that tirzepatide decreases food intake, delays the emptying of the stomach and lowers blood sugar levels. In practice, patients may feel full sooner and have a smaller appetite, although the response differs from one patient to another.

The UAE National Health Survey 2017 to 2018, published by the Ministry of Health and Prevention, found obesity in 27.8% of adults aged 18 to 69. Weight loss medication is generally considered for patients with a BMI of 30 or above, or 27 or above when weight-related health conditions are present. Eligibility also depends on the approved use of each medication. Your endocrinologist will assess whether medication is appropriate based on your individual health and weight profile.

Examples of weight-related conditions include prediabetes, type 2 diabetes, high blood pressure, high cholesterol and obstructive sleep apnoea. Insulin resistance often accompanies metabolic conditions that can affect weight management. It is also associated with increased waist circumference. Our page on Mounjaro and PCOS covers the specific considerations for women with polycystic ovary syndrome.

Patients should not decide by themselves to start a GLP-1 medication. A doctor’s review is critical to ensure the treatment is safe and appropriate for the individual.

Do not use Mounjaro if you or a member of your family has had medullary thyroid carcinoma, or if you have multiple endocrine neoplasia syndrome type 2. The prescribing information lists both as reasons not to use tirzepatide, together with a previous serious allergic reaction to it.

Mounjaro should not be used during pregnancy, as the Mounjaro patient leaflet states. The NHS guidance on tirzepatide advises stopping tirzepatide at least four weeks before you start trying to become pregnant. If you use an oral contraceptive pill, ask your endocrinologist about additional contraception when you start Mounjaro and after each dose increase.

Do not take Mounjaro together with another GLP-1 medication. Your endocrinologist will also ask about any history of pancreatitis, gallbladder disease or severe digestive problems, because the prescribing information carries specific warnings for each.

Tell your endocrinologist and your anaesthetist about Mounjaro before any planned procedure that needs sedation or a general anaesthetic. Mounjaro slows the emptying of the stomach, which can increase the risk of inhaling stomach contents during anaesthesia.

In SURMOUNT-1, a Phase 3 clinical trial in adults with obesity or overweight, patients taking tirzepatide, the active ingredient in Mounjaro, at the highest dose lost an average of around 20% of their total body weight over 72 weeks.

The response was not the same for every participant. The prescribing information for tirzepatide in weight management reports that around nine in ten participants on the 15 mg dose lost at least 5% of their body weight in that trial.

At Endocare, our endocrinologists typically observe weight loss of three to four kilos a month in patients on a medically supervised programme. Our guides to your first month on Mounjaro and to Mounjaro results after two months explain the early weeks of treatment in more detail.

Mounjaro comes in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg. Treatment starts at 2.5 mg once a week. After at least four weeks on a dose, your endocrinologist can increase it in steps of 2.5 mg.

The FDA-approved maintenance doses of tirzepatide are 5 mg, 10 mg and 15 mg once weekly, with 5 mg being the lowest maintenance dose. The prescribing information sets the first increase, to 5 mg, after four weeks, with any further increase in steps of 2.5 mg at least four weeks apart. Our Mounjaro dosage guide explains each step.

The exact pen technique differs by device, so follow the instructions supplied with your prescribed pen. Our guide on how to inject weight loss medication covers the general steps.

Keep unopened pens refrigerated at 2–8°C. The permitted time outside the fridge varies by medication and pen type, so always check the leaflet supplied with your pen. Our article on storing weight loss injections covers storage during the UAE summer.

The digestive side effects reported in 5% or more of patients in the prescribing information include nausea, diarrhoea, vomiting, constipation, indigestion and abdominal pain. Decreased appetite is also reported at this rate. Not every patient experiences them. Side effects such as nausea or constipation can be particularly pronounced in the first few days at a new dose. They often improve as your body adjusts, although some symptoms last longer.

If you experience nausea or constipation, your endocrinologist can adjust the pace of dose increases and, where needed, prescribe medication to help manage these side effects. Our page on Mounjaro side effects covers how often each side effect occurs and how your endocrinologist can manage it.

Seek medical advice immediately if you have severe stomach pain that does not go away, with or without vomiting, as this can be a sign of pancreatitis. Seek medical advice immediately if you have pain in the upper right side of your abdomen, fever or yellowing of the skin or eyes, which can be signs of a gallbladder problem.

The UAE pharmacy price of Mounjaro is AED 1,734 per month. The price is the same at every dose, from 2.5 mg to 15 mg. Endocare adds no markup to the official pharmacy price of your medication.

Mounjaro treatment at Endocare is offered as part of our medical weight loss programme, at AED 2,790 for the first month and AED 2,990 per month thereafter. The programme includes your medication, unlimited specialist consultations and one-to-one coaching during the month, body composition analysis at every visit, scheduled blood tests and free medication delivery across the UAE. For a detailed breakdown of medication and treatment costs, see our Mounjaro cost page.

The table below compares Mounjaro with the Wegovy injection, the Wegovy pill and Foundayo. These figures come from separate clinical trials with different participants and durations. They give a general comparison and do not rank the medications directly.

OptionHow it worksRouteAverage weight loss in trials (% of body weight)
Mounjaro (tirzepatide)Acts on the GIP and GLP-1 receptorsOnce-weekly injectionAround 20% over 72 weeks at 15 mg (SURMOUNT-1 trial)
The Wegovy injection (semaglutide)Acts on the GLP-1 receptorOnce-weekly injectionAround 15% over 68 weeks at 2.4 mg (STEP 1 trial)
The Wegovy pill (oral semaglutide)Acts on the GLP-1 receptorOnce-daily tabletAround 17% over 64 weeks (OASIS 4 trial)
Foundayo (orforglipron)Acts on the GLP-1 receptorOnce-daily tabletAround 12% on average (ATTAIN-1 trial)
 

One 72-week randomised clinical trial, SURMOUNT-5, compared tirzepatide and semaglutide directly in 751 adults with obesity, or overweight with a weight-related condition, who did not have diabetes. In the SURMOUNT-5 trial, patients taking tirzepatide lost around 20% of their body weight on average, against around 14% with semaglutide. Both medications were given at the highest dose each patient could tolerate.

Ozempic contains semaglutide, the same active ingredient as the Wegovy injection, and is approved for type 2 diabetes. Two of our articles look at these options side by side: Mounjaro, Ozempic and Wegovy compared and Foundayo and Mounjaro compared.

Your first consultation

Your first appointment is a full medical assessment, not simply a prescription visit. Your endocrinologist will review your medical history and any relevant blood tests, assess your weight and metabolic health, and discuss whether Mounjaro or another weight loss treatment is the right option for you.

Where possible, your first appointment takes place in person at Endocare’s Dubai clinic, as the physical examination and body composition analysis cannot be completed remotely. Your endocrinologist will review blood tests from the last three months before prescribing.

If your results are out of date, the clinic can arrange the required tests. If they are current, your assessment and prescription can usually be completed at your first appointment. Medication delivery is free across the UAE and typically arrives the same day.

Our pages on Mounjaro in Dubai and Mounjaro in Abu Dhabi explain how to access treatment in each city.

Monthly follow-ups and body composition analysis

Monthly follow-up appointments can be held in person at the clinic or online. At each follow-up, your endocrinologist will review your weight, any side effects and your progress, and agree any change in dose with you.

At Endocare, body composition analysis is included free of charge at every consultation. Body composition analysis estimates body fat, muscle mass and body water. Repeated measurements help your endocrinologist understand how your body is changing beyond the number on the scale.

Nutrition and lifestyle coaching

Endocare’s lifestyle coaches and our clinical nutritionist will work with you on nutrition, movement, sleep and stress. Adequate protein and resistance training can help preserve muscle while you lose weight. Our guide to what to eat on Mounjaro covers meals and portion sizes in more detail.

The generic name for Mounjaro is tirzepatide, which is its active ingredient. The FDA warns that unapproved GLP-1 medications, including compounded tirzepatide, are not reviewed for safety, effectiveness or quality.

Yes. Mounjaro is available in the UAE only on prescription, after a doctor has assessed whether it is appropriate for you. We recommend obtaining it only through a licensed pharmacy. Our article on buying Mounjaro online explains the risks of unregulated sellers.

Some patients start to see weight changes from around week two, while others take longer to respond. Early weight loss also does not necessarily continue at the same rate. Our guide on how long weight loss injections take to work explains the timeline in more detail.

If you miss a dose, take it as soon as possible within four days (96 hours) of the missed dose. If more than four days have passed, skip the missed dose and take the next one on your usual day. The Mounjaro patient leaflet asks for at least three days between two doses.

It can. Mounjaro may make an oral contraceptive pill less effective for four weeks after you start treatment and for four weeks after each dose increase. During these periods, the prescribing information advises switching to a non-oral method of contraception or adding a barrier method.

Some weight regain is possible after stopping. The British Heart Foundation reports an analysis of SURMOUNT-4, a clinical trial in which some participants were switched from tirzepatide to a placebo for a year. In that analysis, 82% of the participants who stopped tirzepatide regained at least a quarter of the weight they had lost. When it is time to come off the medication, your endocrinologist may lower the dose in steps, which is Endocare’s clinical practice, and coaching continues throughout. A gradual reduction in dose is an individual clinical approach, not a proven standard of care, and it has not been shown to prevent weight regain. Our guide on what happens when you stop taking Mounjaro explains what to expect.

Book a Mounjaro consultation at Endocare

At our Dubai clinic, your endocrinologist will assess you, review your blood tests and discuss whether Mounjaro is appropriate for you. You can book a weight loss consultation on +971 4 285 3885 or send us a message on WhatsApp.

Book Your Consultation

Select your location